Exploring Fusobacterium’s Unexpected Benefits in Head &… : Oncology Times
An abstract is unavailable.
Related Articles
Osimertinib With or Without Chemo is Top Choice for Frontline NSCLC
The NCCN guidelines have stated that osimertinib is the preferred category 1 treatment for patients with EGFR-mutated NSCLC discovered before the first line of therapy.
About
NCCN is a not-for-profit alliance of 33 leading cancer centers devoted to patient care, research, and education, is dedicated to improving and facilitating quality, effective,…
AACR Special Conference in Cancer Research: Acute Lymphoblastic Leukemia
AACR Special Conference in Cancer Research: Acute Lymphoblastic Leukemia
Efficacy and safety of TPO receptor agonists in treatment of ITP associated with predominantly antibody deficiencies
Key PointsAfter 6 weeks of treatment, response was achieved in 24 of 28 patients (85.7%).Thrombotic events were reported for 3 patients (10.7%), none of wh
December II, 2024
Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.
ANNUAL REVIEW ISSUE: HAEMATOLYMPHOID MALIGNANCIES: BEYOND THE CURRENT CLASSIFICATIONS: Histopathology: Vol 86, No 1
Click on the title to browse this issue
Five-year Follow-up of a Prospective Food and Drug… : Spine
d fusion (ACDF) control group. Summary of Background Data. Cervical TDR has gained acceptance as a treatment for symptomatic disk degeneration. The design and materials…
Unraveling Sex Differences in Kidney Health and Chronic… : Clinical Journal of the American Society of Nephrology
apparent dimorphism, although the mechanisms underlying these influences remain poorly understood. In this review, we first summarize recent findings on sex differences in the prevalence…
Advancing the Future of Diagnostics and Regulatory Innovations – Friends of Cancer Research
Advancing the Future of Diagnostics and Regulatory Innovations Tuesday, February 4, 2025 10AM – 2PM ET The Ritz Carlton 1150 22nd St NW, Washington, DC…
A Look at Poor Outcomes in Triple-Class Exposed Multiple… : Oncology Times
An abstract is unavailable.